UPDATE ON OPHTHALMOLOGY BUSINESS UNIT T.VPH - Novartis agrees to sell global rights to XIIDRA® and several other ophthalmology products to Baucsh + Lomb
- SIMBRINZA® not included in the divestiture
MONTREAL, July 4, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, notes from the news release issued by Novartis on June 30, 2023 that Novartis has agreed to sell XIIDRA®, a prescription eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease, as well as several other ophthalmology products to Bausch + Lomb Corporation. SIMBRINZA® is not part of the products that are being divested by Novartis. The sale is expected to close before the end of the year.
VALEO PHARMA PROVIDES UPDATE ON OPHTHALMOLOGY BUSINESS UNIT (newswire.ca)